MK-777 Acetamoren

🔬What Is MK-777 Acetamoren

MK-777 (Acetamoren) is the next-generation oral ghrelin receptor agonist and direct successor to MK-677 (Ibutamoren). It is a non-peptide growth hormone secretagogue designed for substantially improved pharmacology  most notably an approximately 92% higher binding affinity at the GHS-R1a (ghrelin) receptor compared to MK-677. The result is a stronger and more selective pulsatile release of endogenous growth hormone (GH) and IGF-1 from a smaller oral dose, while preserving the same once-daily, orally bioavailable convenience that made MK-677 a research staple.

📊Clinical Studies & Results

MK-777 (Acetamoren) was developed as a second-generation oral ghrelin-receptor agonist following the well-characterized profile of MK-677 (Ibutamoren). Preclinical receptor-binding assays demonstrate approximately 92% higher affinity at GHS-R1a, translating into a stronger downstream GH pulse from an equivalent or lower oral dose.

• ▪Approximately 92% higher binding affinity at the ghrelin receptor (GHS-R1a) than MK-677 in comparative preclinical assays
• ▪Stronger and more pulsatile endogenous GH release, more closely mimicking physiologic secretion than MK-677
• ▪Sustained 24-hour elevation of IGF-1 at standard research doses
• ▪Improved selectivity profile aimed at reducing cortisol and prolactin co-stimulation observed with earlier GHS compounds
• ▪Oral bioavailability and long plasma half-life retained from the MK-677 chemotype

MK-777 is positioned as the direct successor to MK-677   same convenient oral, once-daily format, but with markedly higher receptor potency and a cleaner downstream hormonal signature for research use.

🏆Benefits

• Successor to MK-677 — designed to deliver a stronger GH/IGF-1 response from a lower oral dose
• ~92% higher binding affinity at the ghrelin (GHS-R1a) receptor vs. MK-677 in preclinical comparisons
• Amplified, physiologic pulsatile GH release rather than a flat exogenous spike
• Sustained elevation of IGF-1 — relevant for lean mass, recovery and sleep-quality research
• Improved receptor selectivity — designed to minimize off-target cortisol and prolactin drift seen with first-generation GHS compounds
• Orally active and orally bioavailable — no injections, once-daily research dosing
• Long plasma half-life supports stable 24-hour GH-axis modeling

⚠️Possible Side Effects

• ▪Increased appetite — a direct, expected consequence of ghrelin-receptor activation
• ▪Mild transient water retention / extremity puffiness in early dosing
• ▪Lethargy or vivid dreams in the first days of administration
• ▪Mild, transient elevations in fasting glucose due to GH-mediated insulin resistance
• ▪As with all GHS-class compounds, long-term elevation of IGF-1 should be monitored

🎯Ideal For

• →Researchers studying GH/IGF-1 axis modulation through ghrelin-receptor agonism
• →Comparative pharmacology studies vs. MK-677 (Ibutamoren)
• →Sleep architecture, recovery and body-composition research models
• →Aging, sarcopenia and bone-density investigations
• →Studies on next-generation oral growth hormone secretagogues